Ignite Creation Date:
2024-05-06 @ 3:59 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04833140
Status:
RECRUITING
Last Update Posted:
2023-04-11
First Post:
2021-04-03
Brief Title:
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Non-alcoholic fatty liver disease NAFLD is a growing epidemic in the United States Despite this the treatment options remain limited Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis inflammation and fibrosis in non-alcoholic steatohepatitis NASH the progressive form of NAFLD Post-menopausal women are a growing population with particularly high risk of NASH due to their lack of estrogen This study will examine the effect of estradiol on hepatic fibrosis and fat in post-menopausal women with NASH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None